Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of overactive bladder
3.2.1.2 Growing aging population
3.2.1.3 Increasing research investments and activities
3.2.1.4 Growing awareness for early diagnosis and treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with medications and treatment
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porters analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Condition Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Neurogenic bladder overactivity
5.3 Idiopathic bladder overactivity
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Drug therapy
6.2.1 Anticholinergics
6.2.2 Beta-3 adrenoceptor agonists
6.3 Botox treatment
6.4 Neuromodulation
6.5 Other treatment types
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 18-30
7.3 31-50
7.4 51-60
7.5 60 above
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Astellas Pharma Inc.
9.3 Axonics, Inc.
9.4 BlueWind Medical
9.5 Cipla Ltd.
9.6 Endo International plc
9.7 Laborie
9.8 Lupin Ltd.
9.9 Medtronic plc
9.10 Merck & Co.
9.11 Pfizer Inc.
9.12 Sumitomo Pharma America, Inc. (Urovant Sciences)
9.13 Teva Pharmaceutical Industries Ltd.
9.14 Viatris Inc.
9.15 Zydus Lifesciences Ltd.
